Page last updated: 2024-12-11

urolithin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

urolithin B: has antiproliferative activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5380406
CHEMBL ID1526978
CHEBI ID166606
SCHEMBL ID4420540
MeSH IDM000602214

Synonyms (61)

Synonym
MLS000067644
3-hydroxybenzo[c]chromen-6-one
urolithin b
CHEBI:166606
3-hydroxy-benzo[c]chromen-6-one
smr000125059
MLS001049038
CBDIVE_012154
nsc94726
1139-83-9
nsc-94726
OPREA1_202205
OPREA1_232259
STK086550
3-hydroxy-6h-benzo[c]chromen-6-one
NCIOPEN2_005982
AKOS000274161
NCGC00245498-02
NCGC00245498-01
HMS2172E20
b1s2ym5f6g ,
7-hydroxy-3,4-benzocoumarin
6h-dibenzo(b,d)pyran-6-one, 3-hydroxy-
nsc 94726
unii-b1s2ym5f6g
S1321
HMS3319J06
3-hydroxyurolithin
3-hydroxydibenzo-a-pyrone
BBL027918
SCHEMBL4420540
AC-34553
CHEMBL1526978 ,
DTXSID00150610
J-003044
6h-dibenzo[b,d]pyran-6-one, 3-hydroxy-
mfcd00034338
urolithin b, >=95% (hplc)
3-hydroxy-6h-benzo[c]chromen-6-one, aldrichcpr
np755
3-hydroxy-6h-dibenzo[b,d]pyran-6-one
WXUQMTRHPNOXBV-UHFFFAOYSA-N
3-hydroxy-urolithin
DS-9071
Q18395107
CS-0101847
HY-126307
FT-0778245
3-hydroxydibenzo-.alpha.-pyrone
2-biphenylcarboxylic acid, 2',4'-dihydroxy-, .delta.-lactone
3-hydroxy-6h-benzo(c)chromen-6-one
3-hydroxy-6h-dibenzo(b,d)pyran-6-one
3-hydroxy-6-benzo[c]chromenone
A920658
bdbm50521706
SY232456
EN300-186402
urolithinb
Z57108866
nsc823879
nsc-823879

Research Excerpts

Overview

Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA) It has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities.

ExcerptReferenceRelevance
"Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities."( Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
Cao, M; Chen, Q; He, Z; Huang, M; Qing, L; Wu, C; Yan, X; Yu, Z; Zhang, X; Zhao, J; Zhao, Q, 2023
)
3.07

Effects

ExcerptReferenceRelevance
"Urolithin B and auraptene have been reported to exert potent antioxidant effects - however, little is known about the protective effects of these compounds against QA-induced neurotoxicity."( The Effects of Urolithin B and Auraptene on Quinolinic Acid-induced Toxicity in the SH-SY5Y Neuroblastoma Cell Line.
Abbasinezhad-Moud, F; Afshari, AR; Azadi, N; Forouzanfar, F; Jalili-Nik, M; Mirzavi, F; Mohebbati, R; Rakhshandeh, H; Sanati, M; Soukhtanloo, M, 2023
)
1.98

Bioavailability

ExcerptReferenceRelevance
" Due to the not well-established bioavailability of ellagitannins, the mechanisms of observed therapeutic effects following oral administration still remain unclear."( Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials.
Granica, S; Kiss, AK; Melzig, MF; Piwowarski, JP; Schopohl, P; Stefańska, J; Zwierzyńska, M, 2014
)
0.4
"A pilot intervention study was conducted in human volunteers (n = 4) to establish the bioavailability of urolithins, which are the terminal end-products of ellagitannin metabolism by the gastrointestinal microflora."( Pilot walnut intervention study of urolithin bioavailability in human volunteers.
Gehres, N; Haubner, R; Owen, RW; Pfundstein, B; Ulrich, CM; Würtele, G, 2014
)
0.68
" Due to the questionable bioavailability of ellagitannins their gut microbiota metabolites-urolithins have come to be regarded as potential factors responsible for biological activities observed in vivo."( Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages.
Granica, S; Kiss, AK; Moeslinger, T; Piwowarski, JP, 2015
)
0.42
"We investigated the effect of mixing soy protein isolate and pomegranate juice (PJ) on the bioavailability and metabolism of ellagitannins (ETs) in healthy volunteers."( Soy protein isolate does not affect ellagitannin bioavailability and urolithin formation when mixed with pomegranate juice in humans.
Heber, D; Henning, SM; Hsu, M; Lee, R; Li, Z; ManLam, H; Thames, G; Yang, J, 2016
)
0.43
"The consumption of foodstuffs yielding circulating compounds able to maintain endothelial function by improving nitric oxide (NO) bioavailability can be considered as an effective strategy for cardiovascular disease prevention."( Effects on Nitric Oxide Production of Urolithins, Gut-Derived Ellagitannin Metabolites, in Human Aortic Endothelial Cells.
Bonadonna, RC; Brighenti, F; Cito, M; Dei Cas, A; Del Rio, D; Fantuzzi, F; Mena, P; Spigoni, V, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ellagic acid degradation to urolithins011

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency17.78280.044717.8581100.0000AID485294
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
ClpPBacillus subtilisPotency39.81071.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency29.09290.004110.890331.5287AID504467
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency89.12510.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.99530.035520.977089.1251AID504332
importin subunit beta-1 isoform 1Homo sapiens (human)Potency50.11875.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency50.11875.804836.130665.1308AID540263
DNA polymerase eta isoform 1Homo sapiens (human)Potency28.18380.100028.9256213.3130AID588591
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency15.84890.00419.962528.1838AID2675
relaxin receptor 1 isoform 1Homo sapiens (human)Potency14.12540.038814.350143.6206AID2676
neuropeptide S receptor isoform AHomo sapiens (human)Potency5.01190.015812.3113615.5000AID1461
Guanine nucleotide-binding protein GHomo sapiens (human)Potency8.91251.995325.532750.1187AID624287
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency12.58931.000010.475628.1838AID1457; AID901
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)IC50 (µMol)100.00000.51001.64373.1200AID1588066
large T antigenBetapolyomavirus macacaeIC50 (µMol)38.76000.160024.9724100.0000AID1903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 alphaHomo sapiens (human)AC50300.00000.013529.7434171.7000AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
protein O-linked glycosylationPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
O-glycan processingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein O-linked glycosylation via serinePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein O-linked glycosylation via threoninePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein maturationPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
polypeptide N-acetylgalactosaminyltransferase activityPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
protein bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
manganese ion bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
carbohydrate bindingPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
extracellular regionPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
endoplasmic reticulum membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi stackPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi cisterna membranePolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
perinuclear region of cytoplasmPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
Golgi apparatusPolypeptide N-acetylgalactosaminyltransferase 2Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1588066Inhibition of catalytic activity of human recombinant FLAG-tagged ppGalNAcT2 expressed in HEK293T cells and using 5-FAM labelled-EA2 peptide as substrate incubated for 30 mins by HPLC-based enzyme assay2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Inhibition of polypeptide N-acetyl-α-galactosaminyltransferases is an underlying mechanism of dietary polyphenols preventing colorectal tumorigenesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (3.23)29.6817
2010's39 (62.90)24.3611
2020's21 (33.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.91 (24.57)
Research Supply Index4.16 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index48.61 (26.88)
Search Engine Supply Index3.27 (0.95)

This Compound (27.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.61%)5.53%
Reviews2 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (95.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]